Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moshe Talpaz

Showing results (231-240 of 264) with videos related to

Pageof 27
Sort By:
The New England Journal of Medicine|March 2, 2012
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosisSrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Future Oncology (London, England)|August 11, 2022
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosisClaire N Harrison, Vikas K Gupta, Aaron T Gerds, et al.
Haematologica|September 17, 2013
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-ISrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Cancer Discovery|April 6, 2013
Identification of targetable FGFR gene fusions in diverse cancersYi-Mi Wu, Fengyun Su, Shanker Kalyana-Sundaram, et al.
Nature Genetics|November 5, 2013
Activating ESR1 mutations in hormone-resistant metastatic breast cancerDan R Robinson, Yi-Mi Wu, Pankaj Vats, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 15, 2018
Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in OncologyJason Gotlib, Aaron T Gerds, Prithviraj Bose, et al.
The New England Journal of Medicine|March 1, 2002
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemiaHagop Kantarjian, Charles Sawyers, Andreas Hochhaus, et al.
Blood|March 24, 2018
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trialJorge E Cortes, Dong-Wook Kim, Javier Pinilla-Ibarz, et al.
Nature Medicine|March 11, 2025
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trialRaajit K Rampal, Sebastian Grosicki, Dominik Chraniuk, et al.
Leukemia|March 23, 2023
Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy resultsMichael J Mauro, Timothy P Hughes, Dong-Wook Kim, et al.
Pageof 27

Showing results (231-240 of 264) with videos related to

Sort By:
Pageof 27
The New England Journal of Medicine|March 2, 2012
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosisSrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Future Oncology (London, England)|August 11, 2022
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosisClaire N Harrison, Vikas K Gupta, Aaron T Gerds, et al.
Haematologica|September 17, 2013
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-ISrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Cancer Discovery|April 6, 2013
Identification of targetable FGFR gene fusions in diverse cancersYi-Mi Wu, Fengyun Su, Shanker Kalyana-Sundaram, et al.
Nature Genetics|November 5, 2013
Activating ESR1 mutations in hormone-resistant metastatic breast cancerDan R Robinson, Yi-Mi Wu, Pankaj Vats, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 15, 2018
Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in OncologyJason Gotlib, Aaron T Gerds, Prithviraj Bose, et al.
The New England Journal of Medicine|March 1, 2002
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemiaHagop Kantarjian, Charles Sawyers, Andreas Hochhaus, et al.
Blood|March 24, 2018
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trialJorge E Cortes, Dong-Wook Kim, Javier Pinilla-Ibarz, et al.
Nature Medicine|March 11, 2025
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trialRaajit K Rampal, Sebastian Grosicki, Dominik Chraniuk, et al.
Leukemia|March 23, 2023
Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy resultsMichael J Mauro, Timothy P Hughes, Dong-Wook Kim, et al.
Pageof 27